<DOC>
	<DOCNO>NCT01387880</DOCNO>
	<brief_summary>This open , multicenter phase II trial therapy combination cetuximab , irinotecan every second week combine daily dose everolimus patient metastatic colorectal cancer Kirsten rat sarcoma viral oncogene ( KRAS ) mutation patient resistent cetuximab irinotecan therapy metastatic colorectal cancer .</brief_summary>
	<brief_title>Irinotecan , Cetuximab Everolimus Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Main objective : - Number patient progressive disease obtain disease control define sum patient obtain Complete Remission ( CR ) , Partial Remission ( PR , stable disease ( SD ) ) Secondary objective : - Time progression first therapy . - Length disease control ( CR , PR SD ) - Survival date start therapy . - Safety toxicity therapy grade accord Common Toxicity Criteria version 3.0 - Influence smoke disease control , response , survival time progression effect parameter investigation . - Significance metabolic response evaluate Photon Emissions Tomography ( PET ) /Computer Tomography ( CT ) scan . - Blood : Examine influence potential predictive prognostic tumour biomarkers blood lactate dehydrogenase ( LDH ) , Carcinoembryonic antigen ( CEA ) , Vascular endothelial growth factor ( VEGF ) , epidermal growth factor receptor ( EGFR ) , Human Epidermal growth factor Receptor 2 ( HER-2 ) , YKL-40 , Interleukin-6 ( IL-6 ) , metallopeptidase inhibitor 1 ( TIMP-1 ) , procollagen type I N-terminal propeptide ( PINP ) , Procollagen type 3 N-terminal propeptide ( P3NP ) , gen- , micro-ribonucleinate ( microRNA ) - protein array profile , metabolomics C-reactive protein ( CRP ) 2 week start therapy thereafter every 8.weeks disease control , response , survival time progression parameter investigate . - Tissue : Examine possible predictive prognostic biomarkers tissue primary tumour metastases micro-RNAarray profile , mutation K-RAS , murine sarcoma viral oncogene homolog ( BRAF ) , Phosphoinositide 3-kinase ( PIK3CA ) , EGFR , tumor protein 53 ( p53 ) , protein expression polymorphism th phosphatase tensin homolog ( PTEN ) , epiregulin ( EREG ) , amphiregulin ( AREG ) , Insulin-like growth factor 1 ( IGF-1 ) , IGF-1 Receptor ( IGF-1R ) , VEGF , p53 , topoisomerase 1 ( Topo1 ) , YKL-40 , TIMP-1 - Correlation possible predictive prognostic biomarkers blood tissue .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Criteria inclusion : Patients histological cytological verify adenocarcinoma colon rectum nonresectable metastatic cancer . Patients measurable disease without previous radiotherapy Patients metastatic colorectal cancer progression previous therapy 5fluoropyrimidines , oxaliplatin irinotecan . Patients treat oxaliplatin , oxaliplatin contraindicate tolerated patient participate trial . Patients KRASmutation primary tumour metastasis . Patients progression therapy irinotecan cetuximab independent KRAS mutation status . Previous radiotherapy allow less 25 % bone marrow . Age equal 18 year . Performance status less 3 . An expected survival time least 3 month . Signed informed consent accord specification ethical comites . Criteria exclusion : Former concurrent malignant disease except treat basal cell carcinoma situ cervical cancer . No cytotoxic therapy experimental treatment within 28 day inclusion . No former therapy everolimus rapamycin sirolimus temsirolimus . No known hypersensitivity one component therapy . No uncontrolled diabetes No serious nonhealing wound , gastric ulcer , bone fracture , great surgical procedure , major traumatic injury within 28 day inclusion . No ongoing bleed pathological condition associate risk bleed . No liver disease cirrhose , chronical active hepatitis chronic persistent hepatitis . No gastrointestinal disturbance function might cause major change absorption everolimus ulcerative disease , uncontrolled nausea , vomit , diarrhoea , malabsorption syndrome . No planned immunisation attenuate virus study period . Patients unable follow treatment evaluation plan . Every condition therapy judgement investigator might infer patient risk influence trial objective . Pregnant breastfeed woman . At fertile woman insure negative test pregnancy use safe anticonception trial period least 3 month end treatment . Patients active infection serious medical comorbidity , might prevent patient treat protocoled therapy . Incapacitated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Third line therapy</keyword>
	<keyword>Fourth line therapy</keyword>
	<keyword>KRAS mutation status</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Irinotecan</keyword>
</DOC>